• This topic is empty.
Viewing 0 reply threads
  • Author
    • #20628

      A 12-week phase I dose-escalation trial open label has been launched in early 2021 in Japan to evaluate the safety and tolerability of Bosutinib.

      The results of this clinical trial had just been announced.

      Of the nine patients who drank 100-300 milligrams of bosutinib daily for 12 weeks, five stopped progressing, the remaining four remained progressing at the same pace.

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account